Vitamin D supplementation decreases TGF beta-1 bioavailability correlating with clinical improvement in Vitamin D deficient women with PCOS: a randomized placebo-controlled trial

Abstract

Polycystic ovary syndrome (PCOS) affects 5-10% of reproductive-aged women. There is an abnormal increase in transforming growth factor-beta1 (TGF-β1) bioavailability in women with PCOS due to increase in serum TGF-β1 and decrease in its soluble receptor, soluble endoglin (sENG), which has been suggested to play a role in the pathophysiology of this syndrome. Women with PCOS tend to have decreased vitamin D (VD) levels and VD supplementation has been shown to improve various clinical manifestations of PCOS.